Yantai Zhenghai Bio-Tech Co Ltd

Yantai Zhenghai Bio-Tech Co Ltd maintains a strong liquidity position, with a current ratio of 8.6 and no long-term debt, indicating a robust balance sheet and minimal leverage. The company's liquidity_fpt score reflects a low risk of short-term financial distress, supported by a free cash flow of 14.39 million CNY and operating cash flow of 97.19 million CNY. Profitability metrics show a return on equity (ROE) of 9.26% and a return on assets (ROA) of 8.37%, both of which exceed the industry median for medical equipment and biotechnology firms. The company's net income of 82.41 million CNY on revenue of 364.14 million CNY suggests a healthy margin profile, with a gross profit margin of 85.9%. The company operates in a single business segment, with all revenue derived from the sale of biopharmaceutical products. Geographically, the company is concentrated in China, with no disclosed international revenue streams. This concentration may expose the company to regulatory and macroeconomic risks specific to the Chinese market. Looking ahead, the company is projected to maintain stable revenue growth, with a current FY outlook of 5.0% and a next FY outlook of 6.0%. These projections are supported by a growing demand for diabetes management therapies and the company's expanding product portfolio. The company's risk profile is low, with no immediate filing-based liquidity or dilution flags detected. The dilution potential is also low, as the number of basic and diluted shares outstanding remains unchanged at 180 million. No recent equity issuance or ATM/shelf registration activity has been reported. Recent events include the publication of the company's latest financial results and the release of analyst price targets, with a mean recommendation of 1.50 (indicating a "buy" rating) and a mean price target of 23.67 CNY. These signals suggest a positive outlook from the investment community.